Literature DB >> 2396669

Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol.

S Lopez-Hilker1, A S Dusso, N S Rapp, K J Martin, E Slatopolsky.   

Abstract

Phosphorus is a well-known modulator of renal 1 alpha-hydroxylase activity. In early and moderate renal failure it is proposed that dietary Pi reduction ameliorates secondary hyperparathyroidism through increased circulating levels of calcitriol (i.e, 1 alpha, 25-dihydroxycholecalciferol). To gain further insight into the mechanisms by which a low-Pi diet ameliorates secondary hyperparathyroidism in advanced renal insufficiency, studies were performed in five dogs before and 6 mo after the induction of uremia by 5/6 nephrectomy. Glomerular filtration rate decreased from 69.0 +/- 2.3 to 10.5 +/- 0.5 ml/min, immunoreactive parathyroid hormone (irPTH) increased from 66.0 +/- 8.8 to 321.0 +/- 46 pg/ml, and calcitriol decreased from 39.0 +/- 10.4 to 27.0 +/- 6.2 pg/ml. Thereafter, dietary Pi was decreased gradually every 2 wk from 0.95% to 0.6, 0.45, and 0.3%, respectively. Dietary Ca was reduced from 1.6 to 0.6% to prevent development of hypercalcemia. Ionized Ca (ICa) decreased from 5.4 +/- 0.04 to 5.2 +/- 0.05 mg/dl (P less than 0.02), and plasma Pi decreased from 6.3 +/- 0.7 to 4.7 +/- 0.2 mg/dl (P less than 0.05). Calcitriol remained low (23.3 +/- 4.7 pg/ml). However, irPTH gradually decreased from 321.0 +/- 46.0 to 94.7 +/- 22.9 pg/ml (P less than 0.005). These studies indicate that a decrease in dietary Pi from 0.95 to 0.3% suppressed irPTH by approximately 70%. Reduction of irPTH was observed in the absence of a concomitant increase in levels of ICa or calcitriol. These studies suggest that reduction in dietary Pi in advanced renal insufficiency improves secondary hyperparathyroidism by a mechanism that is independent of the levels of calcitriol or plasma ICa.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2396669     DOI: 10.1152/ajprenal.1990.259.3.F432

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  22 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

Review 2.  FGF23 and PTH--double agents at the heart of CKD.

Authors:  Justin Silver; Mariano Rodriguez; Eduardo Slatopolsky
Journal:  Nephrol Dial Transplant       Date:  2012-03-23       Impact factor: 5.992

Review 3.  The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals.

Authors:  Solmaz Khoshniat; Annabelle Bourgine; Marion Julien; Pierre Weiss; Jérôme Guicheux; Laurent Beck
Journal:  Cell Mol Life Sci       Date:  2010-09-17       Impact factor: 9.261

4.  The treatment of renal osteodystrophy.

Authors:  S P Rigden
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

Review 5.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 6.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

7.  Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.

Authors:  Larry A Greenbaum; Ryszard Grenda; Ping Qiu; Irene Restaino; Amy Wojtak; Ana Paredes; Nadine Benador; Joel Z Melnick; Laura A Williams; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

8.  Parathyroid hormone gene expression in hypophosphatemic rats.

Authors:  R Kilav; J Silver; T Naveh-Many
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.

Authors:  E Slatopolsky; J Finch; M Denda; C Ritter; M Zhong; A Dusso; P N MacDonald; A J Brown
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 10.  Calcium, phosphate, vitamin D, and the parathyroid.

Authors:  K H Marks; R Kilav; T Naveh-Many; J Silver
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.